What is the recommended first‑line medication and dosing for opioid withdrawal in an adult with opioid dependence?

Medication for Opioid Withdrawal

Buprenorphine is the recommended first-line medication for opioid withdrawal in adults with opioid dependence, initiated at 4–8 mg sublingual when the Clinical Opiate Withdrawal Scale (COWS) score reaches ≥8 (moderate-to-severe withdrawal), with a target Day 1 dose of approximately 8 mg and standard maintenance dosing of 16 mg daily. 1

Pre-Induction Assessment and Timing Requirements

Before initiating buprenorphine, you must verify the time elapsed since the patient's last opioid use to prevent precipitated withdrawal:

• Wait >12 hours after short-acting opioids (heroin, immediate-release morphine/oxycodone, fentanyl) 1
• Wait >24 hours after extended-release opioid formulations (e.g., OxyContin) 1
• Wait >72 hours after methadone maintenance—for these patients, strongly consider continuing methadone instead of switching to buprenorphine, as methadone has comparable effectiveness and may be safer 1

Confirm active withdrawal using COWS before administering the first buprenorphine dose. A COWS score of 5–12 indicates mild withdrawal (defer buprenorphine), 13–24 indicates moderate withdrawal, 25–36 indicates moderately severe withdrawal, and >36 indicates severe withdrawal. 1 Only initiate buprenorphine when COWS ≥8 to avoid precipitating severe withdrawal. 1

Day 1 Induction Protocol

• Initial dose: Give 4–8 mg sublingual buprenorphine based on withdrawal severity when COWS ≥8 1
• Reassess after 30–60 minutes: If withdrawal persists, provide additional 2–4 mg doses every 2 hours as needed 1
• Target Day 1 total: Approximately 8 mg (range 4–8 mg) 1

Maintenance Dosing

• Standard maintenance dose: 16 mg sublingual daily for most patients—this dose occupies approximately 95% of mu-opioid receptors and creates a ceiling effect on respiratory depression 1
• Dose range: 4–24 mg daily may be used based on individual response 1
• Once-daily dosing is standard; twice-daily dosing (e.g., 8 mg BID) is acceptable but increases respiratory depression risk when combined with benzodiazepines 1

Comparative Effectiveness: Buprenorphine vs. Alternatives

Buprenorphine demonstrates clear superiority over alpha-2 adrenergic agonists (clonidine/lofexidine) with lower average withdrawal scores (mean difference −0.43; 95% CI −0.58 to −0.28) and significantly higher treatment completion rates (risk ratio 1.6; 95% CI 1.2–2.1; number needed to treat = 4). 1, 2

Probability of being the most effective treatment:

• Buprenorphine: 85% 1
• Methadone: 12.1% 1
• Lofexidine: 2.6% 1
• Clonidine: 0.01% 1

Methadone has similar effectiveness to buprenorphine for withdrawal management but is less commonly used in emergency and outpatient settings due to regulatory restrictions requiring in-person dispensing at federally regulated clinics and its long duration of action, which increases opioid toxicity risk if additional opioids are used after discharge. 1, 2, 3

Second-Line Options: Alpha-2 Adrenergic Agonists

Use clonidine or lofexidine only when buprenorphine is contraindicated, unavailable, or the patient declines opioid-based therapy. 1, 4

• Clonidine: 0.1–0.2 mg every 6–8 hours for autonomic symptoms (sweating, tachycardia, hypertension, anxiety); start at low doses and titrate based on withdrawal symptoms and blood pressure monitoring 1, 4
• Lofexidine: Similar efficacy to clonidine but causes significantly less hypotension, making it more suitable for outpatient settings and FDA-approved specifically for opioid withdrawal 4

When using alpha-2 agonists, add symptom-targeted adjunctive medications:

• Antiemetics (promethazine or ondansetron) for nausea/vomiting 1, 4
• Benzodiazepines for anxiety and muscle cramps 1, 4
• Loperamide for diarrhea 1, 4

Management of Precipitated Withdrawal

If buprenorphine precipitates withdrawal (due to premature administration before adequate withdrawal develops), the primary treatment is to administer additional buprenorphine (not less) to re-establish adequate receptor occupancy. 1

Adjunctive symptomatic therapies:

• Clonidine 0.1–0.2 mg every 6–8 hours for autonomic hyperactivity 1
• Antiemetics (promethazine, ondansetron) for nausea 1
• Benzodiazepines for anxiety/muscle cramps 1
• Loperamide for diarrhea 1

Discharge Planning and Long-Term Treatment

• Prescribe 16 mg sublingual buprenorphine-naloxone daily for 3–7 days (or until first follow-up appointment); no refills on initial prescription 1
• The X-waiver requirement was eliminated in 2023, allowing any DEA-licensed provider to prescribe buprenorphine-naloxone 1
• Provide take-home naloxone kit and overdose prevention education 1
• Offer hepatitis C and HIV screening and consider reproductive health counseling 1

Do not discontinue buprenorphine once started for opioid use disorder—abrupt cessation precipitates withdrawal and markedly raises the risk of relapse to more dangerous opioids. 1 There is no predefined maximum duration for buprenorphine maintenance; treatment may be continued indefinitely when clinically indicated. 1 Maintenance therapy is substantially more effective than tapering for preventing relapse in stable adults with opioid use disorder. 1, 5

Critical Safety Considerations

• Screen for QT-prolonging medications (contraindicated with buprenorphine) 1
• Identify high-risk benzodiazepine co-prescribing—FDA black-box warning cites severe respiratory depression and death when combined with buprenorphine 1
• Review state Prescription Drug Monitoring Program (PDMP) before initiating buprenorphine 1

Common Pitfalls to Avoid

• Initiating buprenorphine when COWS <8 precipitates severe withdrawal 1
• Providing buprenorphine to methadone patients earlier than 72 hours after last dose leads to prolonged precipitated withdrawal 1
• Prescribing discharge doses below 16 mg daily often results in persistent withdrawal symptoms and treatment failure 1
• Using alpha-2 agonists as first-line therapy when buprenorphine is available represents suboptimal care 1
• Discharging patients on alpha-2 agonists without a definitive addiction treatment plan, as these agents only address acute withdrawal 1